UPDATE: Morgan Stanley Raises PT on Baxter International on Neutral Risk-Reward
March 25, 2013 at 13:17 PM EDT
In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on Baxter International (NYSE: BAX ), and raised the price target from $71.00 to $84.00. In the report, Lewis noted, “We see a neutral risk-reward into Baxter's highly-anticipated PIII Alzheimer's data. We estimate the stock
